PExA recruit expert in the field of BiomarkerDiscovery
PExA AB (”PExA”) that develop and commercialise an instrument which enable researchers to collect biological material from lung in an non-invasive way to study respiratory diseases, announces the recruitment of Jörgen Östling (PhD), a senior life science researcher. Jörgen will assume his new role as ‘Manager, Biochemical Analysis and Research’ by January 15, 2018.
Jörgen Östling holds a PhD in microbiology and has extensive experience from proteomics and bioinformatics. He has worked more than 20 years within the pharma industry, whereof the last six years focusing on the identification of biomarkers for Precision Medicine in airway diseases like Asthma and COPD. Jörgen is currently an employee at AstraZeneca, where he has been involved in the development of methods for biochemical analyses of PEx-samples.
Jörgen Östling comments
“Since the field of respiratory research has been lacking easy and non-invasive methods for collection of biological material that originate from a site close to where the actual disease process occurs, I became very interested in PExAs method both in terms of its potential in basic science as well as in clinical practice. One of several interesting aspects of PExAs concept is that it opens up for possibilities to develop biomarkers that enables early detection of airway diseases and thus facilitate the development of treatment paradigms that not only aim to relieve symptoms more effectively but also, in prospect may stop or reverse disease progression. It is with passion and great joy I look forward to my new role at PExA.”
Comments from Erik Ekbo, CEO
“We are a company in an exciting phase experiencing increased interest for our technology, and we need to address the further development of different methods for biochemical analysis of PEx-samples. We are therefore very pleased with the recruitment of Jörgen Östling who will bring cutting-edge expertise and provide novel opportunities for our company. In addition to his long standing experience from research aiming at Precision Medicine, Jörgen has an established international network among leading lung researchers and within the pharma industry. These aspects of Jörgens career will be instrumental in our continuous dialogues with customers as well as in establishing research collaborations.”
For further information about PExA, please contact:
Erik Ekbo, CEO
Telephone: +46 723 92 30 30
PExA AB (556956-9246) develops and markets a research instrument with associated products and services to lung researchers for simple and non-invasive sampling, in order to study respiratory diseases such as asthma and chronic obstructive pulmonary disease, COPD. Sampling with PExA can be used to detect lung diseases at an early stage. The sample can be likened to a “blood test for the small airways”. The aim is to facilitate the development of reliable and more individualised diagnosis, monitoring and treatment of respiratory diseases. The original idea and research behind the method comes from the unit for Occupational and Environmental Medicine at the Sahlgrenska Academy at Gothenburg University. Commercial operations started in 2010 with the support of GU Ventures incubator, and the company is founded by inventors, key employees, business angels and GU Ventures. PExA’s B share is listed on AktieTorget.